433226-05-2

Basic information

• Product Name: 3-AMINO-5-BROMO-2-NITROPYRIDINE
• Synonyms: 3-AMINO-5-BROMO-2-NITROPYRIDINE;5-BroMo-2-nitro-3-pyridinaMine;5-BroMo-2-nitropyridin-3-aMine;5-Bromo-2-nitro-pyridin-3-ylamine
• CAS NO: 433226-05-2
• Molecular Formula: C₅H₄BrN₃O₂
• Molecular Weight: 218.01
• Mol File: 433226-05-2.mol

Chemical Properties

• Boiling Point: 404.0±40.0 °C(Predicted)
• Appearance: /
• Density: 1.929±0.06 g/cm3(Predicted)
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: -3.55±0.25(Predicted)
• CAS DataBase Reference: 3-AMINO-5-BROMO-2-NITROPYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-AMINO-5-BROMO-2-NITROPYRIDINE(433226-05-2)
• EPA Substance Registry System: 3-AMINO-5-BROMO-2-NITROPYRIDINE(433226-05-2)

Safety Data

• Hazardous Substances Data: 433226-05-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-Amino-5-bromo-2-nitropyridine is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its presence of functional groups allows for a wide range of chemical reactions, facilitating the development of new drugs with specific therapeutic properties.
Used in Agrochemical Industry:
In the agrochemical sector, 3-amino-5-bromo-2-nitropyridine is utilized as a precursor in the production of agrochemicals. Its reactivity and structural features make it suitable for the synthesis of compounds with pesticidal or herbicidal activities, contributing to the development of effective crop protection agents.
Used in Organic Synthesis:
3-Amino-5-bromo-2-nitropyridine is employed as a versatile building block in organic synthesis. Its ability to participate in various reactions, such as nucleophilic substitution, electrophilic aromatic substitution, and reductive amination, makes it a valuable component in the creation of complex organic molecules.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 3-amino-5-bromo-2-nitropyridine is used as a structural element in the design and synthesis of novel therapeutic agents. Its unique combination of functional groups allows for the development of compounds with specific biological activities, targeting various diseases and medical conditions.
Used in Materials Science:
3-Amino-5-bromo-2-nitropyridine is also utilized in materials science for the development of new materials with unique properties. Its reactivity and structural characteristics make it a promising candidate for the synthesis of advanced materials with applications in various fields, such as electronics, energy storage, and nanotechnology.

Upstream product

• 20826-04-4 5-bromo-3-pyridinecarboxylic acid 
• 13535-01-8 3-amino-5-bromopyridine 
• 152684-24-7 3-bromo-5-(ethoxycarbonyl)aminopyridine 
• 152684-25-8 3-bromo-5-(ethoxycarbonyl)amino-2-nitropyridine 

Downstream Products

• 433226-08-5 2-nitro-5-(4-(tert-butoxycarbonylamino)phenoxy)pyridine-3-ylamine 
• 1254300-83-8 N-(4-fluorobenzyl)-3-hydroxy-7,9-dimorpholino-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide 
• 1097196-50-3 C₁₁H₉N₃O₂ 
• 1609389-83-4 C₃₀H₃₀N₆O₅ 
• 1609389-84-5 C₂₅H₂₂N₆O₃ 
• 1609389-26-5 N-(2-amino-5-phenylpyridin-3-yl)-7-(piperazin-1-yl)quinoline-3-carboxamide 

Relevant articles and documents

Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives as potent HIV-1 NNRTIs

As a continuation of our efforts to discover and develop “me-better” drugs of DAPYs, novel diarylpyridine derivatives were designed, synthesized and evaluated for their anti-HIV activities in MT-4 cells. The majority of these compounds showed high activity against wild-type HIV-1 strain (IIIB) with EC50 values in the range of 0.04–4.41 μM. Among them, compound 5b2 (EC50 = 0.04 μM, SI = 3963) was the most potent. This compound showed anti-HIV-1IIIB activity superior than of Nevirapine but still inferior than of Etravirine. Selected compounds were also evaluated for the activity against reverse transcriptase (RT), and most of the compounds exhibited submicromolar IC50 values indicating they are specific RT inhibitors. Preliminary structure-activity relationships and modeling studies of these new analogues provide valuable avenues for future molecular optimization.

A two-aryl pyridine derivative and its preparation method and application

The invention relates to a diaryl pyridine derivative as well as a preparation method and application thereof. The diaryl pyridine derivative is a compound with a structure shown in a formula I and is a pharmaceutically acceptable salt, ester or prodrug. The invention also provides the preparation method of the compound, and an application of a composition containing one or more of the compounds in preparation medicaments for treating and preventing human immunodeficiency viruses (HIV).

HETERO-HALO INHIBITORS OF HISTONE DEACETYLASE

This invention provides compounds that are inhibitors of HDAC2. The compounds (e.g., compounds according to Formula I, II or any of Compounds 100-128 or any of those in Tables 2 or 3) accordingly are useful for treating, alleviating, or preventing a condition in a subject such as a neurological disorder, memory or cognitive function disorder or impairment, extinction learning disorder, fungal disease or infection, inflammatory disease, hematological disease, or neoplastic disease, or for improving memory or treating, alleviating, or preventing memory loss or impairment.

Aminoheteroaryl benzamides as kinase inhibitors

The present invention provides a compound of Formula (I) or a salt thereof; and therapeutic uses of these compounds. The present invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds with a therapeutic co-agent.

SELECTIVE HDAC1 AND HDAC2 INHIBITORS

Provided herein are compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with HDAC activity, particularly diseases or disorders that involve activity of HDAC1 and/or HDAC2. Such diseases include cancer, sickle-cell anemia, beta-thalassemia, and HIV.

7, 9-NITROGEN RADICAL-4-OXO-4H-PYRIDO[L,2-A]PYRIMIDINE-2-CARBOXYLIC ACID BENZYLAMIDE ANTI-VIRALS

The present invention provides a compound of Formula I or a pharmaceutically acceptable derivative, salt or prodrug thereof. Further provided is a method of treatment or prophylaxis of a viral infection in a subject comprising administering to said subject an effective amount of a compound of Formula I or a pharmaceutically acceptable derivative, salt or prodrug thereof. A pharmaceutical composition or medicament comprising a compound of Formula I is also provided

Design of a series of bicyclic HIV-1 integrase inhibitors. Part 1: Selection of the scaffold

HIV integrase inhibitors based on a novel bicyclic pyrimidinone core is presented. Nine variations of the core scaffold are evaluated leading to optimization of the 6:6 core giving compound 48 with an EC50 of 3 nM against wild type HIV infected T-cells.

Discovery of novel benzimidazoles as potent inhibitors of TIE-2 and VEGFR-2 tyrosine kinase receptors

We herein disclose a novel chemical series of benzimidazole-ureas as inhibitors of VEGFR-2 and TIE-2 kinase receptors, both of which are implicated in angiogenesis. Structure-activity relationship (SAR) studies elucidated a critical role for the N1 nitrogen of both the benzimidazole (segment E) and urea (segment B) moieties. The SAR results were also supported by the X-ray crystallographic elucidation of the role of the N1 nitrogen and the urea moiety when the benzimidazole-urea compounds were bound to the VEGFR-2 enzyme. The left side phenyl ring (segment A) occupies the backpocket where a 3-hydrophobic substituent was favored for TIE-2 activity.

Chemical compounds

Benzimidazole derivatives, which are useful as TIE-2 and/or VEGFR2 inhibitors are described herein. The described invention also includes methods of making such benzimidazole derivatives as well as methods of using the same in the treatment of hyperproliferative diseases.